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ORIGINAL ARTICLE
Anti-Insulin Antibodies and Adverse Events with Biosimilar
Insulin Lispro Compared with Humalog Insulin Lispro
in People with Diabetes
Philip Home, DM,1 Karl-Michael Derwahl, MD,2 Monika Ziemen, MD,3 Karin Wernicke-Panten, MD,3
Suzanne Pierre, MSc,4 Yvonne Kirchhein, PhD,3 and Satish K. Garg, MD5
Abstract
Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog; Ly-Lis). Two
randomized, controlled, open-label, parallel-group, phase 3 studies were conducted to compare the efficacy and
safety of SAR-Lis and Ly-Lis, both in combination with insulin glargine (Lantus). SORELLA 1 was a 12-
month study in 507 people with type 1 diabetes mellitus (T1DM); SORELLA 2 was a 6-month study in 505
people with type 2 diabetes mellitus (T2DM). In this study, the impact of anti-insulin antibodies (AIA) to SAR-
Lis and Ly-Lis on safety and glycemic control is reported.
Methods: AIA were measured regularly throughout both studies at a centralized laboratory blinded to treatment
groups using a drug-specific AIA assay. The AIA status (positive or negative), AIA titers, and cross-reactivity to
human insulin, insulin glargine, and insulin glargine metabolite M1 were analyzed. The potential effect of AIA
on safety, particularly as related to hypersensitivity reactions, hypoglycemia, and treatment-emergent adverse
events, as well as on glycemic control (HbA1c, insulin dose), was evaluated.
Results: AIA positive status at baseline was similar for the two insulins, but higher in T1DM than in T2DM. In
both studies, the percentage of people newly developing AIA in the two treatment groups, or having a ‡4-fold
increase in AIA titers, did not differ. No relationship was observed between maximum individual AIA titers and
change in HbA1c or insulin dose, hypoglycemia, or hypersensitivity reactions or between efficacy/safety
measures and subgroups by presence or absence of treatment-emergent AIA. Hypersensitivity events and events
adjudicated as allergic reactions were few and did not differ between the two groups.
Conclusion: Insulin lispro SAR342434 and the originator insulin lispro had a similar immunogenicity profile in
people with T1DM or T2DM.
Keywords: Anti-insulin antibodies, Biosimilar, Immunogenicity, Insulin lispro, SAR342434.
Introduction
Insulin lispro is the active ingredient of Humalog
 (Eli
Lilly, Indianapolis, IN), a rapid-acting insulin analog
(100U/mL) with faster onset and shorter duration of action
than regular (unmodified) human insulin.1 Humalog (Ly-Lis)
has been approved and marketed for use by people with type
1 (T1DM) or type 2 (T2DM) diabetes mellitus since 1996.
SAR342434 (SAR-Lis; insulin lispro, Sanofi, Paris, France)
has been developed as a biosimilar medicinal product to
Humalog in the EU and as a follow-on product in the United
States in accordance with the relevant EU and US guide-
lines.2–6 Similar pharmacokinetic (PK) and pharmacody-
namic (PD) profiles were demonstrated for SAR-Lis to both
1Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
2Institut fu¨r Klinische Forschung und Entwicklung (IKFE), Berlin, Germany.
3Sanofi-Aventis Deutschland, Frankfurt, Germany.
4Sanofi, Paris, France.
5Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.
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EU-approved and US-approved Ly-Lis and between EU-
approved and US-approved Ly-Lis in a PK/PD study in
people with T1DM using the euglycemic clamp technique.7
No differences in efficacy and safety of SAR-Lis and Ly-
Lis were found in two randomized (1:1), multinational, open-
label, controlled, parallel-group, phase 3 studies in people
with T1DM (SORELLA 1, 12 months) or T2DM (SORELLA
2, 6 months) on a background of insulin glargine (Lantus;
GLA-100, Sanofi) as basal insulin.8,9 In this study, we report
on the immunogenicity profiles of participants from SOR-
ELLA 1 and SORELLA 2, and the potential impact of anti-
insulin antibodies (AIA) on safety and efficacy in the SAR-Lis
and Ly-Lis groups.
Methods
The study design of SORELLA 1 (NCT02273180) and
SORELLA 2 (NCT02294474), as well as participant selec-
tion criteria, disposition, baseline characteristics, and key
efficacy and safety results, have been reported previously.8,9
A total of 1012 people (SORELLA 1, 507; SORELLA 2, 505)
were randomized (1:1) to receive SAR-Lis (N= 506) or
Ly-Lis (N = 506) along with GLA-100. Depending on the
geographical area, people in the Ly-Lis group received US-
approved Humalog (USA, Japan) or EU-approved Humalog
(all other areas). Based on their similar PK/PD profiles, data
from US- and EU-approved Ly-Lis were pooled within dia-
betes type in the comparator group of each study.
Randomization was stratified by HbA1c at screening (<8.0,
‡8.0% [<64, ‡64mmol/mol]), prior use of Humalog/Liprolog
(Yes/No), and geographical region (non-Japan/Japan; SOR-
ELLA 1 only), and was performed centrally by an interactive
voice response system/interactive web response system. SOR-
ELLA 1 involved 89 centers in Europe, Japan, and the United
States,while SORELLA2 involved 103 centers in Europe, South
America, the United States, the Republic of Korea, and Turkey.
Men and women were eligible if ‡18 years old, with T1DM
(SORELLA 1) or T2DM (SORELLA 2) diagnosed for at least
12 months. Criteria for participation included HbA1c in the
range of 7.0%-10.0% (53-86mmol/mol; SORELLA 1) or
6.5%-10.0% (48-86mmol/mol; SORELLA 2) and using
once-daily GLA-100 as basal insulin and insulin lispro (Hu-
malog/Liprolog) or insulin aspart (Novolog/NovoRapid; Novo
Nordisk, Bagsværd,Denmark) as rapid-actingmealtime insulin
at least thrice daily (before each meal) for at least 6 months.
Clinical visits were scheduled at screening, randomization
(day 1), and weeks 4, 8, 12, 20, and 26 (SORELLA 1 and
SORELLA 2), and in SORELLA 1 additionally at weeks 40
and 52. SAR-Lis or Ly-Lis was self-administered by subcu-
taneous injection with an insulin pen within 5–10min before
the start of a main meal (breakfast, lunch, and dinner) and any
additional meals and snacks. Details of the protocols have
been described previously.8,9
Ethical approval according to local regulations was ob-
tained for all study sites. Conduct of the studies adhered to
standards of data collection for clinical trials, according to the
Declaration of Helsinki. Written informed consent was ob-
tained from all participants before starting the studies.
Immunogenicity
Blood samples for determination of AIA were drawn at
least 8 h after last administration of SAR-Lis or Ly-Lis at day
1 and week 4, 12, and 26 in both studies, and at week 40 and
52 in SORELLA 1. Anti-SAR-Lis antibodies were analyzed
at a central laboratory blinded to the treatment group,
employing a quasi-quantitative radioimmunoprecipitation
assay. The assay was validated in accordance with recent
recommendations applying screening, confirmatory, titer,
and cross-reactivity cutpoints.10 Cross-reactivity cutpoints
were validated for human insulin, insulin glargine, and
insulin glargine metabolite M1. The sensitivity of the assay
was 22.1 lg/L; thus the assay was capable of detecting anti-
insulin lispro antibodies with high sensitivity.
The samples were analyzed for AIA status (positive or neg-
ative), titers, and, due to the high amino acid sequence homol-
ogy, AIA cross-reactive to insulin glargine, glargine M1
metabolite, and human insulin. The analysis of AIA data fo-
cused on the change in AIA response observed following the
administration of the investigational medicinal product (IMP)
using the following definitions11: treatment-emergent AIAs
defined as treatment-induced or treatment-boosted AIAs;
treatment-induced AIAs defined as AIAs found de novo (se-
roconversion) following the IMP administration or AIAs de-
tected during IMP administration in participants with missing
baseline sample; and treatment-boosted AIAs defined as pre-
existingAIAs that were boosted to an at least fourfold increase in
AIA titer compared with baseline at any time following the IMP
administration. A fourfold increase in titer corresponds to two
titer steps, while a single titer step would be within the expected
imprecision of the titration method. The analyses were done for
AIA titers (1/dil), representing a quasi-quantitative expression
of the level of AIA in a sample (as recommended in current
literature10). The results are presented for the 12-month period
of SORELLA 1 and the 6-month period of SORELLA 2.
The incidence of AIA was defined as all participants
with ‘‘treatment-boosted’’ or ‘‘treatment-induced’’ AIA (i.e.,
participants with treatment-emergent AIA), while the prev-
alence of AIA was defined as all participants with at least one
positive AIA sample during the study (baseline or treatment
emergent). Peak titers were defined as the maximal individual
titers observed during the on-treatment period. A transient
response was defined as a response detected only once at one
sampling time, except the last, during the on-treatment pe-
riod, or responses detected more often, but where the first and
last AIA-positive samples were <16 weeks apart, and the last
sampling time point was AIA negative.
A persistent response was a response detected at least
twice, where the first and last positive samples were ‡16
weeks apart, or responses detected at the last two sampling
time points irrespective of the time period in between them.
An indeterminate response was a response where only the last
sample was positive. AIA outliers were defined as AIA titer
levels higher than 1.5 times the interquartile range above the
third quartile of distribution of peak AIA titers, correspond-
ing in both studies to AIA titers ‡64 (1/dil).
An Allergic Reaction Assessment Committee (ARAC)
was convened, which consisted of three people who were
specialists in allergy and clinical immunology and one was a
specialist in diabetology with past interest in insulin immu-
nogenicity. Hypersensitivity reactions identified by Medical
Dictionary for Regulatory Activities (MedDRA) search and
potential allergic reactions reported by the investigator on the
dedicated allergic reaction form were reviewed by the ARAC
members who were blinded to the study treatment. For events
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confirmed as allergic, the ARAC proposed a diagnosis and
assessed the possible relationship to IMP and the severity of the
event.
The ARAC also reviewed reports of participants with AIA
titers elevated over the baseline level at the study endpoints
and ongoing hypersensitivity treatment-emergent adverse
events (TEAEs, defined as events that occurred, worsened, or
became serious from first IMP dose up to 1 day after last IMP
dose) and/or ongoing serious adverse events (SAEs), and/or
an increase of HbA1c >1.0% (>11mmol/mol) above baseline,
and/or an unexplained increase in insulin dose (defined as
total daily insulin dose >1.5U/kg or insulin dose increase
>20% above baseline [SORELLA 1] and >2.0U/kg or insulin
dose increase >70% above baseline [SORELLA 2]). The
ARAC assessed if any of these conditions was suspected to be
AIA mediated and provided a recommendation on the need
for follow-up of these participants.
Statistical analysis
Statistical methods for both studies have been reported
previously.8,9 Immunogenicity analyses were descriptive and
based on the AIA population, defined as all participants from
the safety population (all participants randomized and ex-
posed to at least one dose of SAR-Lis or Ly-Lis) with at least
oneAIA sample available for analysis during the on-treatment
period (from first IMP dose up to 1 day after last IMP dose).
Boxplots were provided to assess AIA titers over time.
The potential impact of immune response on safety and ef-
ficacy endpoints was assessed using subgroup analyses of HbA1c
change from baseline to study end, hypoglycemia, injection site
reactions, hypersensitivity reactions, TEAEs, and SAEs by
treatment-emergent AIA (Yes/No). Descriptive statistics
were provided for each subgroup. Least square (LS) means
for the HbA1c analysis by treatment-emergent AIA were
obtained from a mixed-effect model for repeated measures
with treatment group, randomization strata of screening
HbA1c and prior use of Humalog/Liprolog, visit, treatment-
by-visit interaction, AIA subgroup, AIA subgroup-by-treatment
interaction, AIA subgroup-by-visit interaction, and AIA
subgroup-by-visit-by-treatment interaction as fixed categor-
ical effects, and baseline HbA1c value and baseline HbA1c
value-by-visit interaction as continuous fixed covariates.
The significance level of the AIA subgroup-by-treatment
interaction was provided for descriptive purposes to assess
potential heterogeneity of the treatment effect across AIA
subgroups. For hypoglycemia, the significance level of the
AIA subgroup-by-treatment interaction was also provided for
descriptive purposes based on a logistic regression model
with fixed-effect terms for treatment, randomization strata of
screening HbA1c and prior use of Humalog/Liprolog, AIA
subgroup, and AIA subgroup-by-treatment interaction.
Scatterplots were also performed to assess the relationship
between the individual maximal AIA titers during the on-
treatment period and HbA1c change from baseline to study
end, total insulin dose, hypoglycemia, and hypersensitivity
reactions. All analyses were conducted using SAS Enterprise
Guide version 5.1 (SAS Institute, Cary, NC).
Results
In SORELLA 1, 507 people were randomized, of whom
506 received the investigation insulin (SAR-Lis, 252; Ly-Lis,
254). A total of 505 people were randomized and treated in
SORELLA 2 (SAR-Lis, 253; Ly-Lis, 252). Demographic
data were similar between the SAR-Lis and Ly-Lis groups in
both studies and details of these two studies are provided
elsewhere.8,9
Overall efficacy and safety results in the studies did not differ
between the two insulin treatment groups.8,9 Non-inferiority of
SAR-Lis vs Ly-Lis on HbA1c change from baseline at the
prespecified 0.30% (0.33mmol/mol) non-inferiority margin
and inverse non-inferiority were demonstrated at week 26 in
both SORELLA 1 (LS mean difference of SAR-Lis vs. Ly-
Lis: 0.06% [95% CI: -0.08 to 0.20]) and SORELLA 2
(-0.07% [-0.22 to 0.07]). The 6-month extension period for
SORELLA 1 demonstrated that similar glycemic control
was maintained with SAR-Lis and Ly-Lis at similar insulin
dosages over 1 year.8 Changes from baseline to study end in
the daily mealtime and basal insulin dose were small and
similar for the two treatment groups within both studies.8,9
Hypoglycemia and TEAEs did not differ between groups in
either study.8,9
AIA status
The AIA population consisted of 500 participants (SAR-
Lis, 248; Ly-Lis, 252) in SORELLA 1 and 493 participants
(SAR-Lis, 245; Ly-Lis, 248) in SORELLA 2. Similar per-
centages of participants in the two treatment groups were
positive for AIA at baseline, with higher percentages in
SORELLA 1 (SAR-Lis, 47.6%; Ly-Lis, 49.2%) than SOR-
ELLA 2 (SAR-Lis, 24.5%; Ly-Lis, 25.4%) (Table 1).
Similar percentages of participants in the SAR-Lis and Ly-
Lis groups were positive for AIA at least at one time point
(prevalence) between baseline (inclusive) and week 52 in
SORELLA 1 (62.5% and 63.1%) and between baseline (in-
clusive) and week 26 in SORELLA 2 (38.4% and 36.7%).
The percentage of participants in the SAR-Lis and Ly-Lis
groups positive for AIA remained relatively stable during the
on-treatment period in SORELLA 1, being 44.8% and 47.2%,
respectively, at week 52 (Fig. 1A). In SORELLA 2, the
percentages of participants positive for AIA were also similar
between the SAR-Lis and Ly-Lis groups at week 26, with
30.8% and 29.2%, respectively (Fig. 1B).
Median AIA titers were similar at baseline (4.00) between
the two treatment groups in the two studies and remained
relatively unchanged over time with an interquartile range of
2.00–16.00 in the SAR-Lis group and 2.00–8.00 in the Ly-Lis
group in SORELLA 1 (Fig. 2A) and 2.00–8.00 in the SAR-
Lis group and 2.00–16.00 in the Ly-Lis group in SORELLA 2
(Fig. 2B). Maximum AIA titers in T1DM participants
throughout the study (baseline included) were 512 (1/dil) in
the SAR-Lis group and 256 (1/dil) in the Ly-Lis group, and
were 256 (1/dil) in both treatment groups in T2DM partici-
pants. For SAR-Lis in T2DM participants, the maximum of
256 was at baseline; it was 64 postbaseline.
When only people taking insulin lispro (Humalog, US or
EU or Liprolog) before the study were considered, the pro-
portion ‘‘positive’’ at baseline was similar to that in the total
population (above) being 51.4% in SORELLA 1 and 22.7%
in SORELLA 2 (Supplementary Table S1; Supplementary
Data are available online at www.libertpub.com/dia). Pre-
valence in the SORELLA 1 study was 65.8% for SAR-Lis
and 62.0% for Ly-Lis, and in SORELLA 2, 35.4% for SAR-
162 HOME ET AL.
Lis and 33.3% for Ly-Lis. AIA titers remained relatively low
in both treatment groups over the study period in both studies.
Treatment-emergent AIA
The overall percentages of participants with a treatment-
emergent AIA response (incidence) were similar between the
SAR-Lis and Ly-Lis treatment groups during the 12-month
on-treatment period in SORELLA 1 (22.6% and 24.2%) and
the 6-month on-treatment period in SORELLA 2 (18.8% and
14.5%) (Table 1). Treatment-boosted AIA were found in
16.1% of participants in the SAR-Lis group and 21.0% in the
Ly-Lis group in SORELLA 1 and in 20.0% and 12.7% of
participants in SORELLA 2. The median of the individual
peak titers for participants with treatment-boosted AIAs were
16 (1/dil) in the two treatment groups in SORELLA 1 and 12
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FIG. 1. Percentage of participants positive for AIA during 52-week on-treatment period of SORELLA 1 (A) and 26-week
on-treatment period of SORELLA 2 (B)/AIA populations. AIA, anti-insulin antibody; Ly-Lis, insulin lispro; SAR-Lis,
SAR342434.
Table 1. Summary of Anti-Insulin Antibody Response During the On-Treatment
Period in SORELLA 1 and SORELLA 2 – Anti-Insulin Antibody Populations
SORELLA 1 (12 months) SORELLA 2 (6 months)
SAR-Lis
(N = 248)
Ly-Lis
(N = 252)
SAR-Lis
(N = 245)
Ly-Lis
(N = 248)
Participants with AIA positive at baseline, n (%) 118/248 (47.6) 124/252 (49.2) 60/245 (24.5) 63/248 (25.4)
Median titer (1/dil) 4.00 4.00 4.00 4.00
Q1:Q3 2.00:16.00 2:00:8.00 2.00:8.00 2.00:16.00
Participants with ‡4-fold increase in titer
(treatment boosted), n (%)
19/118 (16.1) 26/124 (21.0) 12/60 (20.0) 8/63(12.7)
Median peak titera (1/dil) 16.00 16.00 12.00 16.00
Q1:Q3 8.00:32.00 16.00:32.00 8.00:32.00 8.00:32.00
Transient AIA response, n (%) 0/19 0/26 0/12 0/8
Persistent AIA response, n (%) 19/19 (100) 26/26 (100) 12/12 (100) 8/8 (100)
Indeterminate AIA response, n (%) 0/19 0/26 0/12 0/8
Participants with AIA negative or missing
at baseline, n (%)
130/248 (52.4) 128/252 (50.8) 185/245 (75.5) 185/248 (74.6)
Participants newly positive postbaseline
(treatment induced), n (%)
37/130 (28.5) 35/128 (27.3) 34/185 (18.4) 28/185 (15.1)
Median peak titera (1/dil) 2.00 2.00 2.00 2.00
Q1:Q3 1.00:4.00 1.00:4.00 1.00:8.00 1.00:4.00
Transient AIA response, n (%) 10/37 (27.0) 10/35 (28.6) 8/34 (23.5) 8/28 (28.6)
Persistent AIA response, n (%) 21/37 (56.8) 21/35 (60.0) 15/34 (44.1) 10/28 (35.7)
Indeterminate AIA response, n (%) 6/37 (16.2) 4/35 (11.4) 11/34 (32.4) 10/28 (35.7)
Participants with at least one positive AIA
sample (prevalence)b, n (%)
155/248 (62.5) 159/252 (63.1) 94/245 (38.4) 91/248 (36.7)
Participants with treatment-emergent AIA
(incidence)c, n (%)
56/248 (22.6) 61/252 (24.2) 46/245 (18.8) 36/248 (14.5)
Participants without treatment-emergent AIA, n (%) 192/248 (77.4) 191/252 (75.8) 199/245 (81.2) 211/248 (85.1)
Inconclusive participants, n (%) 0/248 0/252 0/245 1/248 (0.4)
AIA, anti-insulin antibody; dil, dilution; Ly-Lis, insulin lispro; SAR-Lis, SAR243424.
aMaximal titer measured during the on-treatment period.
bPrevalence: participants AIA positive at baseline or with treatment-induced AIAs.
cIncidence: participants with treatment-boosted or treatment-induced AIAs (i.e., participants with treatment-emergent AIAs).
For definition of transient, persistent, and indeterminate responses, see Methods section.
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(1/dil) in the SAR-Lis group and 16 (1/dil) in the Ly-Lis
group in SORELLA 2. In both studies, the AIA response was
persistent in all participants with treatment-boosted AIAs
(Table 1).
A similar percentage of participants in the SAR-Lis and Ly-
Lis groups had treatment-induced AIA in both SORELLA 1
(28.5% and 27.3%) and SORELLA 2 (18.4% and 15.1%)
(Table 1). For these participants, the median of the individual
peak titers was 2 (1/dil) in both treatment groups in the two
studies, whilemaximum titerswere 32 (1/dil) in both treatment
groups in SORELLA 1 and 64 (1/dil) in the SAR-Lis group
and 128 (1/dil) in the Ly-Lis group in SORELLA 2. Differ-
ences between the SAR-Lis and Ly-Lis groups were minimal
in both studies, and the percentage of participants with a
transient AIA response was similar in both treatment groups
(SORELLA 1: SAR-Lis 27.0%, Ly-Lis 28.6%; SORELLA 2:
SAR-Lis 23.5%, Ly-Lis 28.6%) (Table 1).
When only participants taking insulin lispro (Humalog, US
or EU, or Liprolog) before the study were considered, the
proportions with treatment-emergent AIAs were similar to
the total study populations (above), being 21.9% and 22.8%
for SAR-Lis and Ly-Lis in SORELLA 1, and 16.2% and
15.1% in SORELLA 2 (Supplementary Table S1).
Cross-reactivity
The proportion of participants with antibodies cross-
reacting with human insulin at each visit was similar be-
tween the two groups and ranged between 87.2% and 94.7%
during the 12-month on-treatment period in SORELLA 1
and between 80.3% and 96.8% during the 6-month on-
treatment period in SORELLA 2. The proportion of par-
ticipants with antibodies cross-reacting with GLA-100 or
insulin glargine metabolite M1 at each visit ranged from
84.4% to 92.7% and 71.0% to 79.7%, respectively, in
SORELLA 1 and from 81.0% to 89.9% and 65.2% to 85.5%,
respectively, in SORELLA 2.
Influence of AIA on efficacy and safety outcomes
The mean change in HbA1c from baseline to study end in
SORELLA 1 and SORELLA 2 was similar for the SAR-Lis
and Ly-Lis groups in both participants with and without
treatment-emergent AIA (Table 2). The treatment-by-
treatment-emergent-AIA interaction showed no heterogeneity
of treatment effect across the two subgroups of AIA status in
SORELLA 1 (P= 0.42) or SORELLA 2 (P= 0.69). There was
no relationship observed between the change inHbA1c and the
individual maximal AIA titers in either study (Fig. 3A, C).
Daily doses for basal, mealtime, and total insulin were
generally comparable across treatment groups and were in-
dependent of the presence of treatment-emergent AIA (Ta-
ble 2). The mean dose changes from baseline to week 52
(SORELLA 1) and week 26 (SORELLA 2) did not suggest
use of higher insulin doses in participants with treatment-
emergent AIA compared with those without treatment-
emergent AIA, and in the context of the HbA1c, findings do
not suggest specific unmet need. No relationship was ob-
served between the individual maximal AIA titers and the
change in total daily insulin dose from baseline to end of
treatment in the two studies (Fig. 3B, D).
In both studies, the number of participants with AIA titers
‡64 (1/dil) for treatment-emergent AIAs was small and
similar in both treatment groups (SORELLA 1: SAR-Lis,
four participants; Ly-Lis, five participants; SORELLA 2:
SAR-Lis, two participants; Ly-Lis, one participant). The re-
view of HbA1c, insulin doses, and safety parameters (hy-
persensitivity event and hypoglycemia) in these participants
did not suggest negative effects of high AIA titers on these
measures in either treatment group. There was no relationship
observed in either study between the individual maximum
AIA titers and the rate of hypoglycemia events per year
(shown for severe hypoglycemia and documented symp-
tomatic hypoglycemia [<3.0mmol/L; 54mg/dL]) or hyper-
sensitivity events (Fig. 4).
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FIG. 2. Boxplots of AIA titer (1/dil) over time during the 52-week on-treatment period in participants with T1DM
(SORELLA 1) (A) and the 26-week on-treatment period in participants with T2DM (SORELLA 2) (B)/AIA populations.
AIA, anti-insulin antibody; Ly-Lis, insulin lispro; SAR-Lis, SAR342434; T1DM, type 1 diabetes mellitus; T2DM, type 2
diabetes mellitus. At each visit, AIA titers are described for participants with a positive-sample AIA status at the visit. The
boxplot provides the 25% (Q1), 50% (median), and 75% (Q3) quartiles (lower, middle, and upper horizontal bars of the box,
respectively). The diamond represents the mean, and triangles or squares represent values beyond the upper/lower whiskers
(defined as 1.5 times the interquartile range). Each symbol for high/low values could represent more than one participant.
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In participants with treatment-emergent AIA, severe hy-
poglycemia was reported by 10 people (17.9%) in the SAR-
Lis group (1-4 events per person and one person with 122
events discussed below) and six people (9.8%) in the Ly-Lis
group (1-5 events per person) in SORELLA 1 (Table 3). In
most episodes of severe hypoglycemia, the symptoms re-
ported by participants were weakness/palpitation/increased
sweating/nervousness/confusion/headache/dizziness/tremor.
One person in the SAR-Lis group reported 122 hypoglyce-
mia events (119 reported during the first 6 months of the study)
requiring assistance in the form of oral carbohydrates and thus
classed as severe hypoglycemia. None of the hypoglycemia
was reported as requiring other forms of carbohydrate admin-
istration, glucagon, or other resuscitative actions. In none of the
episodes in this person were severe neuroglycopenic symptoms
reported. The site did not believe all events truly required as-
sistance. Notably, HbA1c had improvedmarkedly in this person
during the study (baseline: 9.4%; week 26: 7.4%) and AIAs
were detectable at week 12 only (titer: 1 [1/dil]).
In SORELLA 2, no one in the SAR-Lis group and one
participant in the Ly-Lis group reported severe hypoglycemia
among participants with treatment-emergent AIA (Table 3). In
those participants without treatment-emergent AIAs, severe
hypoglycemia was reported by 23 people (12.0%) in the
SAR-Lis group (1-4 events per person) and 28 people
(14.7%) in the Ly-Lis group (1-5 events per person) in
SORELLA 1, and by 6 people (3.0%) in the SAR-Lis group (1
event per person) and 2 people (0.9%) in the Ly-Lis group
(1 event per person) in SORELLA 2. The treatment-by-
treatment-emergent-AIA interaction showed no heterogeneity
of treatment effect for any hypoglycemia category.
In both treatment groups in both studies, hypersensitivity
events were reported by few participants with treatment-
emergent AIAs. In both studies, the incidence of hyper-
sensitivity reactions was greater in both treatment groups in
participants without treatment-emergent AIAs compared
with the group of participants with treatment-emergent AIAs
(Table 3). Across both studies, TEAEs were adjudicated by
ARAC as allergic reactions in four participants (0.8%) in the
SAR-Lis group (seasonal allergy, contact dermatitis, allergic
rhinitis, and allergy to arthropod bite) and four participants
(0.8%) in the Ly-Lis group (urticaria, allergic rhinitis,
–0.8
–0.6
–0.4
1 2 4 8 16 32 64 128 256 512
Da
ily
 
to
ta
l in
su
lin
 
do
se
(U/
kg
)
ch
an
ge
 fr
om
ba
se
lin
e 
to
w
e
e
k 
52
D
ai
ly 
to
ta
l in
su
lin
 d
os
e(U
/kg
) c
ha
ng
e
fro
m
 b
as
el
in
e 
to
 w
ee
k 
26
Maximal AIA titer (1/dil) - Log2 (scale)
–0.2
0.0
0.2
0.4
0.6
0.8
           –1.4
–0.7
1 2 4 8 16 32 64 128 256
Maximal AIA titer (1/dil) - Log2 (scale)
–0.0
0.7
1.4
2.1
2.8
3.5
–4
–3
–2
1 2 4 8 16 32 64 128 256 512
H
bA
1c
 
(%
) c
ha
ng
e f
rom
 ba
se
lin
e t
o w
ee
k 5
2
Maximal AIA titer (1/dil) - Log2 (scale)
–1
0
1
2
3
4
5
6
Ly-Lis
–3.5
–3.0
–2.5
1 2 4 8 16 32 128
H
bA
1c
 
(%
) c
ha
ng
e f
rom
 ba
se
lin
e t
o w
ee
k 2
6
Maximal AIA titer (1/dil) - Log2 (scale)
–2.0
–1.5
–1.0
–0.5
0.0
0.5
1.0
1.5
64 256
SAR-Lis SAR-Lis
Ly-Lis
SAR-Lis
Ly-Lis
SAR-Lis
Ly-Lis
A B
C D
FIG. 3. Scatterplots of the change from baseline in HbA1c (A, C) and total insulin dose (B, D) to week 52 in SORELLA 1
(A, B) and to week 26 in SORELLA 2 (C, D) by maximum individual AIA titers/AIA populations. Ly-Lis, insulin lispro;
SAR-Lis, SAR342434.
166 HOME ET AL.
pruritus, and mouth swelling). None of the allergic reactions
in either study was considered related to the investigational
insulin and none was suspected to be AIAmediated. Injection
site reactions occurred in very few participants: 0–3 partici-
pants/group in both studies regardless of AIA status.
In SORELLA 1, the percentage of participants with any
TEAE was similar in the SAR-Lis and Ly-Lis groups in those
with (53.6% and 52.5%, respectively) or without (55.2% and
57.1%, respectively) treatment-emergent AIA (Table 3). In
SORELLA 2, the percentage of participants with any TEAE
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was slightly higher in the SAR-Lis group (45.7%) than in the
Ly-Lis group (38.9%) in people with treatment-emergent AIA
and similar between the groups in people without treatment-
emergent AIA (SAR-Lis, 46.2%; Ly-Lis, 43.6%), with no
single TEAE accounting for the difference. The most fre-
quently reported TEAEs at the primary system organ class
(SOC) level were infections and infestations in both SOR-
ELLA 1 (SAR-Lis, 32.5%; Ly-Lis, 31.9%) and SORELLA 2
(SAR-Lis, 20.2%; Ly-Lis, 16.3%). TEAEs in the other SOCs
were reported in less than 10%–11% of participants regardless
of treatment group.
The percentage of participants with serious TEAEs was also
similar in the two treatment groups in SORELLA 1 regardless
of AIA status, with slightly higher percentages in people
without treatment-emergent AIA (Table 3). In SORELLA 2,
the percentage of participants with serious TEAEs was higher
in the Ly-Lis group than the SAR-Lis group with (11.1% vs.
4.3%) or without (10.0% vs. 5.0%) treatment-emergent AIA,
with no single SAE accounting for the difference.
There were 13 cases in SORELLA1 (SAR-Lis, 5; Ly-Lis, 8)
and four cases in SORELLA 2 (SAR-Lis, 1; Ly-Lis, 3) with
AIA titers elevated above the baseline value at study endpoint
and concomitant ongoing hypersensitivity events or potential
indicators of deterioration of glycemic control. The ARAC did
not suspect these cases to be AIAmediated and did not deem it
necessary to follow up with the people in any of the cases.
Discussion
Regulatory guidelines for approval of biosimilar (follow-on)
pharmaceuticals, mainly proteins and including insulin, gen-
erally require clinical studies of immunogenicity lasting 1 year
notably in the United States (as mandated by the U.S. Food and
Drug Administration).2,12 This can be traced to problems with
some biosimilar products in the past because pharmaceutical
proteins are potentially antigenic in humans,13 and because
immunogenicity is one of the ways to detect impurities left
over frommanufacturing. Indeed for insulin, in particular up to
the 1970s, immunological problems were not uncommon,
something that can be traced to the continued presence of in-
sulin and proinsulin derivatives rather than the small changes
in amino acid sequence of the then animal insulins.14
However with the introduction of chromatographic
manufacturing procedures, immunological insulin resistance
and injection site changes decreased significantly. Low titers
of insulin antibodies are usual, however, even in those ex-
posed only to human insulin. This seems to be related to the
development of low levels of insulin derivatives in the late
stages of manufacturing, and storage of insulin thereafter.14
Furthermore, many people with diabetes, especially T1DM,
have detectable levels of insulin antibodies as part of the
pathological process of the condition, even before they re-
ceive insulin products.15
Thus, as in this study, sensitive assays will uncover low
serum levels of insulin antibodies, even in those taking, or
only exposed to, modern insulin analogues. The proportion of
people found to be ‘‘positive’’ will vary with the sensitivity of
the assay, and here in people with T1DM, this approaches
50%, although lower in people with T2DM, with their dif-
ferent human leukocyte antigen profile. This is consistent
with previous studies for lispro insulin, which also noted that
lispro insulin performed similarly in terms of antibody status
to human insulin.16
When exposed to SAR-Lis compared with Ly-Lis, the
changes in antibody profile, whether viewed as those with
treatment-emergent positivity, a clinically significant rise in
titers, or those with higher titers, did not differ, implying that
the immunogenicity of SAR-Lis did not differ from Ly-Lis.
Adjudicated changes in glucose control (as HbA1c) or insulin
dose (i.e., to detect immunological insulin resistance in oc-
casional individuals) failed to detect any single case on either
insulin. Further the distribution of changes in HbA1c and
insulin dose implies no relationship to insulin antibody titers
even at the highest titers seen, implying that the sensitivity of
the assay is such that the antibody levels detected even on
dilution to 1:64 or higher are too low to influence insulin
Table 3. Event Table for Severe Hypoglycemia, Hypersensitivity Reactions, Injection Site Reactions,
Treatment-Emergent Adverse Events, and Serious Adverse Events with Treatment-Emergent
Anti-Insulin Antibodies in SORELLA 1 and SORELLA 2 – Anti-Insulin Antibody Populations
SORELLA 1 (52 weeks) SORELLA 2 (26 weeks)
Treatment-emergent AIA Treatment-emergent AIA
Yesa No Yesa No
SAR-Lis
(N = 56)
Ly-Lis
(N = 61)
SAR-Lis
(N = 192)
Ly-Lis
(N = 191)
SAR-Lis
(N = 46)
Ly-Lis
(N = 36)
SAR-Lis
(N = 199)
Ly-Lis
(N = 211)
Hypoglycemia, n (%)
Severe hypoglycemia 10 (17.9) 6 (9.8) 23 (12.0) 28 (14.7) 0 1 (2.8) 6 (3.0) 2 (0.9)
Hypersensitivity reactions and injection site reactions, n (%)
Any hypersensitivity
reactions
1 (1.8) 2 (3.3) 14 (7.3) 14 (7.3) 1 (2.2) 1 (2.8) 8 (4.0) 8 (3.8)
Any injection site reactions 0 2 (3.3) 3 (1.6) 1 (0.5) 1 (2.2) 1 (2.8) 0 3 (1.4)
TEAEs and SAEs, n (%)
Any TEAE 30 (53.6) 32 (52.5) 106 (55.2) 109 (57.1) 21 (45.7) 14 (38.9) 92 (46.2) 92 (43.6)
Any SAE 4 (7.1) 6 (9.8) 16 (8.3) 13 (6.8) 2 (4.3) 4 (11.1) 10 (5.0) 21 (10.0)
aParticipants with preexisting AIAs that were boosted to a significant higher titer (at least fourfold increase) compared to baseline, or
participants without preexisting AIA (or missing baseline) and with at least one positive AIA sample.
TEAE, treatment-emergent adverse event; SAE, serious adverse event; SAR-Lis, SAR34243.
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absorption, insulin availability in the plasma or extracellular
space, or insulin-receptor interactions.
There are statistical limitations to our approach, indeed
generally in the insulin antibody area. As noted above, the sit-
uation differs from exposure to a new biopharmaceutical (such
as an anti-tumor necrosis factor agent) because at baseline, our
populations have high percentages of ‘‘positive’’ individuals,
with the median around the limit of detection. The phenome-
non of regression to the mean will then indicate that any sub-
population (such as those deemed ‘‘negative’’ or ‘‘positive’’ in
line with consensus recommendations10) will tend to the orig-
inal distribution on retesting, such that there will be a high
conversion in either direction even without any intervention.
In insulin studies, there is always an intervention even in the
control group, but, in a high proportion of those randomized,
Lilly lispro was swapped to Ly-Lis. Nevertheless, in these
participants, an apparent insulin antibody response was seen in
a large proportion of those previously ‘‘negative’’, and en-
hanced levels in others. It seems likely that this is simple re-
gression toward the original distribution. This also explains
why the apparent prevalence of positivity increased during the
study, more and more individuals having the chance of at least
one positive result.
As in those randomized from Lilly lispro to SAR-Lis, the
findings are very similar to those randomized from Lilly
lispro to Ly-Lis; the implication is that there was no detect-
able immunological effect of the biosimilar lispro beyond
that of prior insulins. Since the findings for those coming into
the study from Lilly lispro are close to those for the whole
study, the implication is that the background antigenicity for
those coming off other analogues (mainly insulin aspart) was
also the same both before and during the study and inde-
pendent of exposure to SAR-Lis or Ly-Lis.
It should be noted that as well as statistical effects, con-
current medical conditions, such as infections or autoimmune
disease, might be expected to boost insulin antibody titers in a
few individuals as part of more general immunological ac-
tivation. However, while the numbers are small, there is no
imbalance between the SAR-Lis and Ly-Lis treatment groups
in ‘‘treatment-boosted’’ titers.
Other immunological phenomena related to insulin ther-
apy include skin reactions rarely and hypersensitivity reac-
tions extremely rarely. No signal for any difference for these
was found in our studies, but the expected incidence would be
too low to detect even quite a large change, given the pop-
ulation exposures we used. Hypoglycemia has been related to
very high antibody titers notably in neonates.14 In SORELLA
1, numbers of participants with severe hypoglycemia in the
overall population were 34 in both treatment groups, and too
small to be meaningful in SORELLA 2. No other immuno-
logically or non-immunologically related adverse events
differed between the treatment groups.
We conclude that the biosimilar (follow-on) insulin lispro
SAR342434 and the originator insulin lispro had a similar
immunogenicity profile in people with T1DM and T2DM.
They have no relevant association with surrogate clinical
outcomes in either population.
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